Growth hormone treatment in irradiated children with brain tumors.
We assessed the efficacy of GH treatment in 25 GH deficient patients irradiated for brain tumors (eight with glioma cranio-irradiated, eleven with medulloblastoma and six with ependymoma craniospinal-irradiated). We administered GH at doses of 0.6-0.9 IU/kg/week for one to three years at least two years after diagnosis of the tumor. We assessed the efficacy of the treatment each year by comparing the values of height velocity over bone age and change in the ratios progression of chronological age/progression of bone age and progression of statural age/progression of bone age. The treatment promoted satisfactory growth; better results were obtained in patients with glioma, who received cranial irradiation only, than in those with medulloblastoma or ependymoma, who received spinal irradiation as well. Moreover, the growth prognosis improved, especially in the cranio-irradiated patients. In our series of patients four presented tumor recurrence; these results did not differ significantly from those in irradiated patients with cerebral tumors who were not treated with GH.
Corrias
A
A
Division of Pediatric Endocrinology, Regina Margherita Children's Hospital, Turin, Italy.
Picco
P
P
Einaudi
S
S
de Sanctis
L
L
Besenzon
L
L
Garrè
M L
ML
Brach del Prever
A
A
de Sanctis
C
C
D000293:Adolescent; D000365:Age Determination by Skeleton; D001827:Body Height; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002528:Cerebellar Neoplasms / Q000532:radiotherapy; D002648:Child; D002675:Child, Preschool; D004806:Ependymoma / Q000532:radiotherapy; D005260:Female; D005910:Glioma / Q000532:radiotherapy; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local; D011878:Radiotherapy / Q000009:adverse effects*
D019382:Human Growth Hormone